Eric Rovner led the review process.
Original Clinical Article
Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria: A prospective open-label long-term study using frequency–volume chart†
Article first published online: 28 OCT 2011
Copyright © 2011 Wiley Periodicals, Inc.
Neurourology and Urodynamics
Volume 31, Issue 1, pages 80–85, January 2012
How to Cite
Kojima, Y., Sasaki, S., Imura, M., Kubota, Y., Hayashi, Y. and Kohri, K. (2012), Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria: A prospective open-label long-term study using frequency–volume chart. Neurourol. Urodyn., 31: 80–85. doi: 10.1002/nau.21224
- Issue published online: 23 JAN 2012
- Article first published online: 28 OCT 2011
- Manuscript Accepted: 5 SEP 2011
- Manuscript Received: 27 JUN 2011
- Scientific Fund of the Japan Health Science Foundation
- Japanese Ministry of Education, Culture, Science and Technology. Grant Numbers: 19659416, 19791117, 20591886, 21791516, 21791518
- Japanese Foundation for Prostate Research
- Naito Foundation
- Japan Research Foundation for Clinical Pharmacology
- Ichihara International Scholarship Foundation
- Suzuken Memorial Foundation
- α1-AR antagonist;
- benign prostatic hyperplasia;
- nocturnal polyuria
The effects of tamsulosin treatment on changes in frequency–volume chart (FVC) data, especially nighttime urine production, over time were assessed, and the mechanisms underlying the improvement of nocturia in benign prostatic hyperplasia (BPH) patients with nocturnal polyuria (NP) are discussed.
A total of 104 patients with lower urinary tract symptoms secondary to BPH were enrolled. After enrollment in the study, the patients were treated with tamsulosin (0.2 mg) once daily. Visits were scheduled every 4 weeks until week 12 (month 3) after study entry, and then every 12 weeks subsequently. All patients completed the International Prostate Symptom Score (IPSS), quality of life (QOL) index, and 3-day FVC, and underwent uroflowmetry at enrollment and on each visit.
Eighty-two patients (mean age: 70.9 ± 7.1 years) were analyzed for 24 months after treatment. Patients were divided into two groups, NP and nonNP, based on FVC outcome. The IPSS, QOL index, and maximum flow rate improved during the 24-month period after treatment in both groups. Mean daytime urine volume significantly increased in the NP group, but no changes were detected in the nonNP group. Mean nighttime urine frequency significantly decreased in the NP group over a 24-month period, and was associated with a significant decrease in nighttime urine volume that was not found in the nonNP group. Maximum voided volume increased most months after treatment in both groups.
The present long-term prospective study using FVC demonstrated that tamsulosin reduced nighttime urine production in BPH patients with NP. Neurourol. Urodynam. 31:80–85, 2012. © 2011 Wiley Periodicals, Inc.